HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE
https://doi.org/10.20996/1819-6446-2015-11-1-79-84
Abstract
Aspects of heart rate-lowering therapy in patients with chronic heart failure using If-channel blocker ivabradine are discussed. The evidence-based data on ivabradine use reveal its advantages, disadvantages and place in the treatment of cardiac patients.
About the Authors
S. V. Shalaev
Regional Cardiology Clinic of Tyumen Regional Hospital №1, Tyumen State Medical Academy
Russian Federation
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia
Odesskaya ul. 54, Tyumen, 625023 Russia
L. V. Silicic
Tyumen State Medical Academy
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia
O. V. Abaturova
Tyumen State Medical Academy
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia
Russian Federation
Odesskaya ul. 46A, Tyumen, 625023 Russia
References
1. Cohn J.N., Levine T.B., Olivari M.T. et al. Plasma norepinephrine as a guide to prognosis with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
2. Hasenfuss G., Holubarsch C., Herman H.P. et al. Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with nonfailing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994; 15: 164-70.
3. Bohm M., Schwinger R.H., Koch A. et.al. The failing humen heart is unable to use the Frank-Starling mechanism. Circ Res 1994;74:959-69.
4. Green S.J., Vaduganathan M., Wilcox J.E. et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm. Heart Failure 2013; 6: 488-06.
5. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected of proven coronary artery disease. Eur Heart J 2005;26:967-74.
6. Fox K., Ford I., Steg P.G. et al. Ivabravin for patient with stable coronary artery disease and left –ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372: 807-16.
7. Habal MV, Liu PP, Austin PC, et. al. Association of heart rate at hospital discharge with mortality and hospitalization on patients with heart failure. Circ Heart Fail 2014;7(1):12-20.
8. Rienstra M., Damman K., Mulder B.A. et. al. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC: Heart Fail 2013;1(1): 21-8.
9. Lechart P., Hulot J.S., Escolano S. et al. Heart rate cardiac rhytm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-33.
10. Gullestad L., Wikstrand J., Deedwania P., et al., MERIT – HF Study Group. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/ Extended Release Randomized Intervention Trial in Cronic Heart Failure (MERIT –HF). J Am Coll Cardiol 2005:45;252-9.
11. Hartmann F, Katus HA. Beta blockers in heart failure therapy with special reference to the COPERNICUS Study. Herz 2002;27 Suppl 1:30-4.
12. Lugai MI, Lysenko AF. Analysis of drug therapy for coronary heart disease in Ukraine: results of the PULSAR. Ukrainskiy Kardiologicheskiy Zhurnal 2010; 3: 36-43. Ukrainian (Лугай М.И., Лысенко А.Ф., Анализ медикаментозной терапии ишемической болезни сердца в Украине: результаты исследования PULSAR. Украинский Кардиологический Журнал 2010;3: 36-43).
13. Wood S. Right drugs, inadequate dose: do AMI performance measures need dosing data? Available at: http// www.medscape.com/viewarticle/809807. Assessed by 03.02.2015.
14. McAlister F.A. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-94.
15. Bucchi A., Baruscotti M., DiFrancesco D. Current-dependend block of rabbit sino-atrial node If channel by ivabradin. J Gen Physiol 2002;120:1-13.
16. Camm A.J., Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradin (S16257) in adult patient with normal electrophysiology. Drug R D 2003;4:83-9.
17. Vilaine J.P., Bidouard J.P., Lesage L., et al. Anti-ischemic effects of ivabradin, a selective heart-rate reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardioveasc Pharmacol 2003;42:688-96.
18. Borer J.S.,Bohm M., Ford I., et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systole heart failure: the SHIFT Study. Eur Heart J 2012;33 (22):2813-20.
19. Swedberg K., Komajda M., Bihm M. et al. On behalf of the SHIFT investigators ivabradine and outcomes in chronic failure (SHIFT): a randomized placebo-controlled study. Lancet 2010;275:875-85.
20. Bohm M., Borer J.S., Ford I., et. al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure analysis from the SHIFT study. Clin Res Cardiol 2013;102(1):11-22.
21. Borer J.S., Bohm M., Ford I., et. al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113(3):497-503.
Review
For citations:
Shalaev S.V., Silicic L.V., Abaturova O.V. HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE. Rational Pharmacotherapy in Cardiology. 2015;11(1):79-84. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-1-79-84
Views:
875
Email this article 